Therapy understanding and health related quality of life in stage III/IV melanoma patients treated with novel adjuvant therapies.

OBJECTIVE: Our aims were to investigate the motivation for therapy, the understanding and valuation of potential treatment toxicities in melanoma patients offered adjuvant therapies. METHODS: Between September 2018 and September 2019 49 adjuvant patients with stage III and IV melanoma received a self-created, pre-treatment questionnaire. Furthermore, the patients were handed out the REPERES-G, EQ-5D-3L and EORTC QLQ C-30 questionnaires. RESULTS: Eight patients (18.3 %) decided against adjuvant therapy (mean age 71.6 years). Four of these had stage IIIA melanoma. The majority of patients (73.4 %) decided for adjuvant treatment with PD1-inhibitors despite their potential high grade, persistent, irreversible or even fatal toxicities. About a third of patients with BRAF V600 mutated melanoma who decided for therapy chose targeted therapy (31.3 %). These patients were younger (mean age 49 years), still working and had families with children. The REPERES-G questionnaire showed that our patients were generally satisfied with medical care. The average scores in the EQ-5D-3L and EORTC QLQ C-30 questionnaires indicated good subjective general health. CONCLUSIONS: Despite the associated toxicities as well as the required time and effort for a one-year treatment the majority of patients decided for adjuvant treatments.